Tagrisso-Orpathys OS Win in MET-Mutant NSCLC: First-Mover Precision Play, Magnitude Unknown

AstraZeneca's Tagrisso Combination Extends Lung Cancer Survival

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys demonstrated extended overall survival and delayed disease progression or death compared to chemotherapy in patients with EGFR-positive non-small cell lung cancer driven by a MET mutation. These patients had previously experienced disease worsening after first- or second-line treatment with Tagrisso. The companies aim to establish this combination as the first biomarker-directed, all-oral treatment option globally for this specific patient population.

• The combination of Tagrisso and Orpathys significantly extended overall survival and delayed disease progression or death when compared to chemotherapy. This outcome represents a crucial advancement for patients facing this specific type of lung cancer.
• The trial focused on patients with EGFR-positive non-small cell lung cancer, specifically those with a MET mutation, whose disease had progressed following initial or subsequent Tagrisso treatment. This highlights the targeted nature of the therapy for a challenging patient group.
• AstraZeneca and Hutchmed are committed to developing the combination as the first biomarker-directed, all-oral treatment option for this setting worldwide. This strategic goal underscores the potential for a convenient and effective therapeutic approach.

Addressing Challenges in Advanced EGFR-Positive NSCLC with MET Mutation

Treatment of EGFR-positive NSCLC with concurrent MET dysregulation presents a multifaceted clinical challenge, driven by diagnostic heterogeneity, evolving resistance mechanisms, and variable therapeutic outcomes. The complexity of this molecular landscape demands both precise biomarker stratification and carefully balanced combination strategies.

• Lack of consensus on MET dysregulation definitions: No standardized definition exists for MET dysregulation in EGFR-mutant NSCLC. Detection methodologies — including FISH, IHC, NGS, and digital PCR — differ in speed, cost, and specificity, with particular difficulty in distinguishing focal MET amplification from MET polysomy. Biomarker analyses indicate that MET focal amplification and overexpression are complementary in predicting clinical benefit from MET inhibition, while arbitrarily defined AXL dysregulation thresholds risk diluting the apparent efficacy of AXL-targeted blockade.

• Acquired resistance to EGFR-TKIs: Patients treated with osimertinib invariably develop acquired resistance through mechanisms including additional EGFR mutations, MET amplification, and AXL overexpression — the latter mediated via upregulation of the PI3K/AKT and MAPK/ERK1/2 pathways. The oncogenic MUC1-C protein has further been identified as a driver of acquired osimertinib resistance, being upregulated in drug-tolerant persister cells and necessary for reactivation of the EGFR pathway.

• Marked variability in treatment response by biomarker profile: Response rates to MET-targeting combination regimens differ substantially depending on the underlying molecular profile. For ningetinib plus gefitinib, the ORR is 30.8% in MET-amplified tumors, 0% in MET polysomy, and 24.1% in MET-overexpressing tumors. Patients with concurrent MET amplification and AXL overexpression achieve an ORR of 80% and DCR of 100%, yet this co-occurring profile is present in only 6.8% of patients — significantly limiting its clinical applicability.

• Toxicity burden of combination and triplet regimens: More intensive combination strategies, while potentially offering greater efficacy, carry substantially increased toxicity. The triplet regimen of amivantamab with lazertinib and chemotherapy demonstrated the highest incidence of severe-grade adverse events across evaluated treatment options, despite its capability to prolong progression-free survival — underscoring the need for careful benefit-risk assessment in treatment selection.

Unpacking the Design and Outcomes of the Tagrisso-Orpathys Trial

The landscape of clinical trials investigating EGFR-positive NSCLC with MET alterations spans multiple treatment strategies, from MET-directed combinations with first-generation EGFR inhibitors to bispecific antibody approaches. The trials summarized below reflect a range of study designs — from randomized placebo-controlled phase II studies to retrospective single-center analyses — each contributing distinct insights into therapeutic targeting of the EGFR/MET co-alteration axis.

Positioning Tagrisso-Orpathys in the Evolving NSCLC Treatment Landscape

In EGFR-mutated NSCLC patients with acquired MET alterations following EGFR-TKI therapy, dual EGFR-MET inhibition has demonstrated consistently superior efficacy over EGFR-TKI monotherapy. A meta-analysis pooling 562 patients across six studies reported a combined objective response rate (ORR) of 49.2% (95% CI: 0.402–0.582), a disease control rate (DCR) of 78.6% (95% CI: 0.680–0.893), and a median progression-free survival (PFS) of 5.62 months. These aggregate findings are reinforced by individual trial data: in a randomized phase II study of 30 patients with MET-amplified NSCLC following osimertinib progression, savolitinib plus osimertinib yielded an ORR of 57% and a median PFS of 7.4 months, compared to 13% and 1.6 months, respectively, with savolitinib monotherapy. In biomarker-enriched subgroups defined by high MET expression (IHC 3+ ≥90% tumor cells) or elevated gene copy number (≥10), responses were further improved, with ORR reaching 63% and median PFS of 8.2 months for the combination arm.

The generation of EGFR-TKI used in combination with MET inhibition also influences outcomes. Pairing a MET-TKI with a third-generation EGFR-TKI yielded numerically improved results versus a first-generation EGFR-TKI combination in T790M-negative patients with MET-dependent resistance, with ORRs of 56.8% versus 47.8%, DCRs of 81.6% versus 75.0%, and median PFS of 7.45 versus 4.55 months (p = 0.05). Across the major MET-TKIs — capmatinib, savolitinib, and tepotinib — efficacy appeared broadly comparable when each was combined with an EGFR-TKI, with ORRs of 47.7%, 50.7%, and 48.8%, respectively (p = 0.96), and median PFS values of 5.49, 6.88, and 5.48 months (p = 0.56). Differences in DCR were statistically significant across agents (p = 0.02), warranting further investigation.

Safety profiles across MET-TKI combinations showed meaningful differences that may inform clinical selection. Grade ≥3 treatment-related adverse events were reported in 30.0%, 46.7%, and 41.2% of patients receiving capmatinib-, savolitinib-, and tepotinib-based regimens, respectively (p = 0.07), with capmatinib demonstrating numerically lower hepatotoxicity as measured by AST and ALT elevations. In a real-world retrospective analysis of 20 patients treated with osimertinib combined with crizotinib, capmatinib, savolitinib, or tepotinib, the ORR was 34.8%, tumor shrinkage was observed in 82.4% of evaluable patients, and the median time on treatment reached 27 months — reflecting durable clinical benefit in routine practice. Collectively, these data position dual EGFR-MET inhibition as a clinically meaningful strategy in this molecularly defined patient population, with third-generation EGFR-TKI-based combinations offering an efficacy advantage in acquired resistance settings.

Extending Targeted Therapy in Post-Osimertinib, MET-Driven NSCLC

The landscape of non-small cell lung cancer (NSCLC) treatment has been profoundly reshaped by targeted therapies, particularly for patients harboring EGFR mutations. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, has become a standard first-line treatment, offering significant benefits. However, the challenge of acquired resistance remains, with a substantial proportion of patients eventually experiencing disease progression. Among the various resistance mechanisms, MET amplification has emerged as a critical driver of treatment failure following initial osimertinib therapy.

The recent data on the combination of osimertinib and savolitinib (Orpathys) represents a pivotal step forward in addressing this unmet medical need. This all-oral, biomarker-directed regimen has demonstrated extended overall survival and delayed disease progression or death in EGFR-mutated NSCLC patients whose tumors developed MET amplification after prior osimertinib treatment. Clinical studies have shown encouraging objective response rates, with evidence suggesting better outcomes in patients with higher MET gene copy numbers. This targeted approach offers a compelling alternative to traditional chemotherapy, which often comes with a broader toxicity profile and less durable responses in this specific population.

However, the introduction of any new combination therapy necessitates a careful consideration of its implications and potential challenges.

• Managing Cumulative Toxicity: While the safety profile of osimertinib plus savolitinib has been reported as consistent with the individual drugs, the combination of two TKIs means clinicians must remain vigilant for cumulative adverse events, including dermatological issues, gastrointestinal disturbances, and the rare but serious risk of interstitial lung disease.

• Precision in Patient Selection: The observed trend of improved efficacy with higher MET amplification levels underscores the importance of precise biomarker testing. Defining optimal MET gene copy number cutoffs will be crucial to ensure that only patients most likely to benefit receive this targeted combination.

• Anticipating Future Resistance: While this combination effectively targets MET-driven resistance, new resistance mechanisms will eventually emerge. Ongoing research will be vital to characterize these subsequent pathways and develop strategies for further lines of therapy, ensuring continuous innovation in the fight against advanced NSCLC.

This development not only offers a new therapeutic avenue but also reinforces the evolving paradigm of precision oncology, where comprehensive molecular profiling guides sequential treatment decisions, ultimately aiming to extend and improve the lives of patients.